Physician profile
Stephen W Shield
NPI 1073590071
$53,880.37
in general payments reported to CMS, 2019-2025
41 companies · $7,469 in 2025
The $7,469 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,469 · 2020: $1,532 · 2021: $1,831 · 2022: $4,175 · 2023: $17K · 2024: $17K · 2025: $7,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $9,802 · Consulting Fee: $7,400 · Travel and Lodging: $2,463 · Education: $23.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,185.00 |
| Food and Beverage | $9,801.85 |
| Consulting Fee | $7,399.89 |
| Travel and Lodging | $2,462.75 |
| Education | $23.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26,560.46 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genentech USA, INC. | $12,369.04 | 2019-2025 | Xolair |
| Csl Behring | $2,388.56 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,849.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,298.54 | 2019-2025 | |
| Pfizer INC. | $1,000.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $966.63 | 2020-2025 | Takhzyro, Cuvitru |
| Grifols USA, LLC | $828.87 | 2019-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.38 | 2019-2023 | Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $720.44 | 2019-2025 | Dupixent |
| Optinose US, INC. | $658.98 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $578.30 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $565.66 | 2021-2025 | Orladeyo, Orladeyo |
| Kaleo, INC. | $444.56 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $352.82 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Shield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.